Previous Article | Next Article 
Infection and Immunity, April 2001, p. 2383-2389, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2383-2389.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Expression of Chlamydia pneumoniae
Polymorphic Membrane Protein Family Genes
Jane
Grimwood,1,
Lynn
Olinger,1 and
Richard S.
Stephens1,2,*
Francis I. Proctor Foundation, University of
California, San Francisco,1 and Division
of Infectious Diseases, School of Public Health, University of
California, Berkeley,2 California
Received 17 October 2000/Returned for modification 7 December
2000/Accepted 8 January 2001
 |
ABSTRACT |
The genome of the obligate intracellular bacterium Chlamydia
pneumoniae CWL029 encodes a family of 21 proteins with predicted outer membrane localization. These polymorphic membrane proteins (Pmps)
are heterogeneous in both amino acid sequence and predicted size but
are unified by the conserved amino acid motifs GGAI and FXXN repeated
in the N-terminal half of each protein. Reverse transcriptase PCR
analysis showed that all pmp genes are transcribed. To
determine whether all proteins are expressed, specific antisera were
generated by immunization with mutually exclusive synthetic peptides
representing each of the 21 predicted Pmps. Each antiserum reacted
with, and was typically immunospecific for, the corresponding peptide
immunogen by enzyme-linked immunosorbent assay. Western blot analyses
of purified elementary bodies showed that 11 of the 21 Pmps were
detectable. Attempts to demonstrate by Sarykosyl fractionation that the
Pmps were localized to the outer membrane revealed that several of the
Pmps were unstable and readily degraded. Analyses of additional
C. pneumoniae strains showed that although some Pmps are
conserved, others vary between strains, in both molecular weight and
level of expression.
 |
INTRODUCTION |
Chlamydia pneumoniae has
been recognized as an important cause of acute respiratory tract
infections, including pneumonia, pharyngitis, and bronchitis
(6). It is estimated that 50 to 70% of adults are
seropositive, with primary infection occurring in teenage years and
prevalence rising with age (3). Recent attention has
focused on the association between C. pneumoniae and
atherosclerosis (5, 12). The biology of
Chlamydia is characterized by its obligate intracellular
growth and by a unique biphasic developmental cycle, alternating
between an infectious extracellular form, the elementary body (EB), and
the metabolically active intracellular form, the reticulate body.
Proteins exposed on the surface of infectious organisms are primary
mediators in pathogen infection and transmission. The recent completion
of the C. pneumoniae CWL029 genome sequence has provided
complete information on the coding capacity of this organism, including
a comprehensive group of genes that are predicted to encode surface
proteins (9). The C. pneumoniae genome encodes a family of 21 polymorphic membrane proteins (Pmps), which are predicted to be localized to the bacterial outer membrane
(9). These proteins are polymorphic in amino acid sequence
and predicted size but are related by the conserved amino acid motifs
GGAI and FXXN, which are repeated numerous times in the amino-terminal half of each protein (8, 9). Phylogenetic analysis groups these proteins into six related families, implying at least six specific roles for the proteins in chlamydial biology (8).
Variation in amino acid sequence or expression of surface proteins of
some infectious organisms plays a vital role in establishing an
infection and ensuring pathogen survival. This variation can be seen in
phase, functional, and antigenic diversity (1, 4). The
function of the Pmps in Chlamydia growth and development
remains unknown. Indeed, it is unknown whether the variation evidenced by the genome sequence is utilized by the bacterium during its developmental cycle, for interaction with the host cell, or between strains. The aim of this study was to use existing genome sequence data
and, through functional genomics, to examine Pmp expression at both the
transcriptional and translational levels.
 |
MATERIALS AND METHODS |
Cell lines and bacterial strains.
HEp-2 cells were routinely
grown in Iscoves's modified Dulbecco's medium (University of
California San Francisco Cell Culture Facility) supplemented with 10%
fetal calf serum, 0.1 mg of vancomycin per ml, and 0.1 mg of
streptomycin per ml. C. pneumoniae strains CWL029 (kindly
provided by C. Black, Centers for Disease Control and Prevention),
TW-183, and AR-29 (both kindly provided by C.-C. Kuo, University of
Washington) were centrifuged onto HEp-2 cells and incubated for 72 h in the presence of 1 µg of cycloheximide per ml as previously
described (7). EB were purified on discontinuous Renografin (E. R. Squibb & Sons, Princeton, N.Y.) density
gradients as previously described (11) and frozen at
80°C until use.
RT-PCR analysis.
Oligonucleotide primers were designed to
amplify a 300 to 400-bp fragment of each pmp gene (Table
1). Total RNA was extracted from
uninfected HEp-2 cells and C. pneumoniae CWL029-infected HEp-2 cells at 72 h postinfection. Trizol (Life Technologies, Rockville, Md.) was added directly to the cell monolayers, and RNA was
extracted and purified as specified by the manufacturer. RNase-free
DNase (Life Technologies) was used to ensure complete removal of
contaminating DNA. cDNA was transcribed from 2 µg of each RNA, using
1 µM of the reverse oligonucleotide primer and murine leukemia virus
reverse transcriptase (RT) (Promega, Madison, Wis.). The DNA was then
amplified by PCR using 1 µM of each oligonucleotide primer and
Taq polymerase (Perkin-Elmer, Foster City, Calif.). To
ensure chlamydial specificity, reactions were performed for each gene
using uninfected HEp-2 host cell RNA. In addition, matched reactions in
mixtures lacking RT were performed for each gene to ensure complete
removal of contaminating DNA.
Selection and conjugation of synthetic peptides.
Table
2 lists the 20-mer peptides selected for
synthesis. Peptides were selected from the C. pneumoniae
CWL029 genome sequence as being specific for each of the Pmps based on
the following criteria: they (i) were less than 50% identical to any
other 20-mer stretch of amino acids in the entire genome, (ii) did not
contain any long stretches of internal hydrophilic residues, and (iii) did not contain any internal cysteine residues. A second peptide was
chosen for a Pmp when the first failed to generate an antibody that
recognized EB protein by immunoblot analysis. When the Pmp contained
predicted frameshifts, the second peptide was chosen from the opposite
side of the frameshift from the first peptide. All peptides had a
C-terminal cysteine added to the native sequence to facilitate
conjugation. Peptides were synthesized using solid-phase techniques by
Genemed Synthesis Inc. (South San Francisco, Calif.) and conjugated to
keyhole limpet hemocyanin (KLH) using Sulfo-SMCC cross-linker (Pierce,
Rockford, Ill.).
Immunizations.
Six-week-old BALB/c mice were injected
intraperitoneally with KLH-conjugated peptide suspended in complete
Freund's adjuvant (Sigma, St. Louis, Mo.). Five mice were immunized
per group. Control mice received unconjugated KLH. The mice were
boosted subcutaneously on days 14 and 28 with conjugated peptide
suspended in incomplete Freund's adjuvant. The animals were
exsanguinated on day 38, and their serum was frozen at
20°C.
Indirect enzyme-linked immunosorbent assay to determine the
antipeptide antibody titer.
Polystyrene 96-well plates (Immulon 2;
Dynex Technologies, Chantilly, Va.) were coated for 3 h at 37°C
with unconjugated peptide or KLH (100 ng/well) in phosphate-buffered
saline (PBS) (pH 7.4). The wells were then blocked with 5% dried
nonfat milk in PBS-0.1% Tween 20 (PBS-Tween) overnight at 4°C.
Subsequently, the plates were incubated for 1 h with dilutions of
sera in PBS-Tween and then for 1 h with a 1:10,000 dilution of
horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G
antibodies (Promega). All incubations were carried out at 37°C;
washes were done with PBS-Tween. Bound antibody was detected using
3,3,'5,5'-tetramethylbenzidine (Sigma). Absorbance values were read at
450 nm.
Preparation of the chlamydial outer membrane complex (COMC).
Purified C. pneumoniae EB were suspended in PBS containing
2% Sarkosyl (Sigma) and 5 mM EDTA and incubated for 30 min at 37°C. Detergent-insoluble complexes were pelleted by centrifugation (10,000 × g). The pellet was suspended in 2% Sarkosyl with
5 mM MgCl2 and digested with 50 µg of DNase per ml and 50 µg of RNase per ml for 30 min at 37°C. Insoluble material was
pelleted by centrifugation (10,000 × g), washed once
with PBS, and suspended in PBS.
Pmp protein stability.
To determine Pmp protein stablity,
purified C. pneumoniae EB were suspended in PBS containing
2% Sarkosyl and 5 mM EDTA. Protease inhibitors were added to aliquots,
and samples were removed at various times and analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting (see below). The following protease inhibitors
(Boehringer-Mannheim, Indianapolis, Ind.) were evaluated: antipain
dihydrochloride (50 µg/ml), bestatin (40 µg/ml), chymostatin (60 µg/ml), E-64 (10 µg/ml), leupeptin (5 µg/ml), pepstatin (0.7 µg/ml), phosphoramidon (300 µg/ml), Pefabloc (1 mg/ml), and
aprotinin (2 µg/ml).
SDS-PAGE and immunoblot analysis.
Proteins of purified
chlamydial EB and COMC were solubilized in SDS sample buffer containing
50 mM dithiothreitol, heated to 100°C for 5 min, and separated by
SDS-PAGE (8% polyacrylamide gels). Proteins were visualized using
Coomassie blue stain or electrotransferred to nitrocellulose membranes.
The membranes were blocked overnight at 4°C in PBS containing 5%
bovine serum albumin. They were then incubated for 1 h at room
temperature in primary antibody diluted 1:1,000 in PBS-3% bovine
serum albumin. After they were washed in PBS-Tween to remove unbound
antibody, bound antibody was detected using a 1:5,000 dilution of
anti-mouse alkaline phosphatase secondary antibody (Promega). A
stabilized alkaline phosphatase substrate solution (Promega) was used
for colorimetric detection.
 |
RESULTS |
All pmp genes are transcribed during infection.
To
determine pmp transcription during chlamydial growth, total
RNA from C. pneumoniae-infected HEp-2 cells was isolated and analyzed by RT-PCR using primers specific for each of the 21 genes. As
a control, analyses were also carried out for each gene using uninfected HEp-2 cells. Transcripts were detected for each gene, demonstrating that all pmp genes are transcribed during
infection (Fig. 1). This included six
pmp genes that were predicted to be truncated because of
frameshifts; therefore, even genes that are apparently not capable of
producing a functional protein are transcribed.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of pmp gene transcription. Each
pmp gene was amplified by RT-PCR using primer pairs listed
in Table 1 and with C. pneumoniae DNA as a positive control.
RNA obtained from uninfected or infected cells was used as the template
with or without RT in the assay mixture.
|
|
Generation of antisera specific for each Pmp.
To determine
whether pmp genes are translated during infection, 21 groups
of mice were immunized with synthetic peptides specific for each of the
Pmp proteins. By ELISA, each antiserum reacted with its corresponding
peptide immunogen to very high titer, with the weakest reactivity
providing 50% of the maximum titer of 1:16,000 (data not shown).
Although each peptide immunogen was selected for lack of amino acid
sequence identity, the 21 antisera were tested for reactivity to each
of the 21 peptides by ELISA. Mutually exclusive reactivity for the
homologous serum-peptide pairs was shown for each with a few exceptions
(Fig. 2). Antisera for PmpB/C showed
detectable cross-reactivity to peptides representing PmpG2, PmpG3,
PmpG5, PmpG6, PmpG11, and PmpG12. Likewise, the antisera from some of
these G family-based peptides also cross-reacted to the B/C peptide,
thus having a two-way cross-reaction, with the exception of PmpG4,
PmpG6, and PmpG12. Several antisera displayed nonreciprocal
cross-reactivity, including PmpG3-reactive serum to PmpG5 peptide,
PmpG6 serum to PmpG12, PmpE/F4 serum to PmpE/F2, and PmpA serum to
PmpE/F4.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 2.
Specificity of Pmp peptide-elicited sera. Strong
reactivity, represented by filled squares, was found for each serum to
each peptide used for immunization by ELISA following adsorption of
peptide to wells of microtiter plates. If the reactivity of a peptide
had a twofold or greater optical density with respect to that of the
homologous reaction, it is shown as a filled square.
|
|
Pmp expression during infection.
Since each of the
pmp genes was transcribed, protein expression was evaluated
by immunoblotting of C. pneumoniae CWL029 EB lysates using
each of the peptide-specific antisera. Of the 21 sera, 8 (anti-PmpG2,
anti-PmpG6 through anti-Pmp9, anti-PmpG13, anti-PmpH, and anti-PmpE/F2)
detected strong immunospecific antigens and 2 sera (anti-Pmp-G11 and
anti-Pmp-E/F1) reacted weakly to antigens with molecular weights of
approximately 90,000 to 100,000 (Fig. 3).
A weak band for anti-PmpE/F4 was revealed in some experiments but not
others. No Pmp-specific reactivity was detected for the remaining sera
by immunoblot analysis regardless of high antipeptide reactivity.
Despite the cross-reactivity observed for some of the Pmp sera by
peptide ELISA, such as PmpB/C sera with PmpG-family proteins, these
sera did not react to C. pneumoniae proteins by immunoblot
analysis. Therefore, at least half of the transcribed pmp
genes are translated into stable proteins; however, the presence of
weakly reactive bands should be interpreted with caution since we
cannot unequivocally rule out the possibility that these are weak
because they are due to cross-reactivity with other Pmps. Two
immunoblot-detected proteins did not show a molecular weight similar to
that predicted by the coding sequence. PmpG6 migrated at approximately
100,000 (Fig. 3), although it is predicted to encode a 144-kDa protein.
PmpG11 was consistently detected as a set of doublet antigens with
molecular weights of approximately 105,000 and 110,000 (Fig. 3). PmpG8
revealed an additional component of ~80,000 (Fig. 3).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Detection of Pmps in EB lysates of CWL029 using a
peptide-derived serum in immunoblots. This is a composite figure
following analysis of each of the 21 Pmp sera. Prominent immunoreactive
bands are present at molecular weights of approximately 90,000. pmpG3, pmpG4, pmpG5, pmpG10, pmpG12, and pmpE/F3
are not predicted to produce proteins because of gene sequence
frameshifts or truncation. The sizes of molecular weight markers are
shown on the left in thousands.
|
|
Because some of the pmp genes in CWL029 have predicted
frameshifts (8, 9) (PmpG3, PmpG4, PmpG5, PmpG10, PmpE/F3)
or are truncated (PmpG12), it was not surprising that sera specific for
these proteins did not detect antigens in EB lysates. For the
frameshifted genes, peptides were synthesized and antisera were
produced to each of the polypeptides flanking the frameshift, but none
of these paired sera reacted by immunoblot analysis (data not shown).
However, the pmpG1, pmpA, pmpB/C, and pmpD genes
are complete (8, 9) and were transcribed, but no specific
detectable bands were observed by immunoblot analysis, suggesting that
these are either not stable or not translated.
Variation in protein stability among different Pmps.
The COMC
is structurally unique among bacteria and is operationally defined as
consisting of the proteins that remain in a macromolecular complex
following extraction with Sarkosyl and are not found in the soluble
fraction without the addition of a reducing reagent such as
dithiothreitol or 2-mercaptoethanol (2). At least two of
the Pmp proteins for C. psittaci and C. pneumoniae are expressed and localized to the surface of EB
(10, 14). Initial testing of Pmp sera by immunoblotting
COMC preparations gave inconsistent results since Pmp sera that
detected antigens using EB lysates either revealed bands in both the
insoluble and soluble fractions or, paradoxically, were not detected in
either fraction. For example, PmpG2 was detected in the COMC-insoluble fraction and a weaker antigen was also seen in the soluble fraction (Fig. 4). For PmpH, although strongly
present in EB lysates, an immunoreactive band was not detected in
either the COMC-insoluble or -soluble fractions (Fig. 4). Among the
Pmps detected in EB lysates, PmpE/F2, PmpE/F4, PmpG8, PmpG13, and PmpH
were notably absent following Sarkosyl extraction whereas PmpG2, PmpG6,
PmpG7, PmpG9, and PmpG11 were detected in COMC preparations (data not shown).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
Instability of Pmps following Sarkosyl lysis of EB.
Immunoblots of EB in SDS sample buffer (EB) and the insoluble (OMC) and
soluble (SOL) fractions following extraction in Sarkosyl are shown. The
immunoblots were probed with PmpG2- or PmpH-specific sera. The sizes of
molecular weight markers are shown on the left in thousands.
|
|
The finding that some of the Pmps were present in EB lysates but not
detectable in either the COMC-insoluble or -soluble fractions suggested
that these Pmps were not stable during the solubilization procedure. To
test this hypothesis, samples were withdrawn at different times
following the addition of Sarkosyl, immunoblotted, and probed with
anti-PmpG2 and anti-PmpH. A progressive loss of protein was observed
over the time of incubation for PmpH but not for PmpG2 (Fig.
5). To test whether these were lost to
proteolysis, a variety of protease inhibitors were added with the
Sarkosyl solubilization buffer and probed with anti-PmpH. Antipain
dihydrochloride and, especially, chymostatin significantly prevented
the loss of immunoreactivity detected by immunoblot analysis (Fig.
6). These data show that PmpH is
susceptible to proteolysis, probably by an endogenous chlamydial
protease released following lysis by Sarkosyl.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5.
Degradation of PmpH following Sarkosyl extraction of EB.
Aliquots were collected at 10 and 20 min following the addition of 2%
Sarkosyl and probed by immunoblot analysis using either anti-PmpG2 or
anti-PmpH sera.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
Inhibition of PmpH degradation by addition of protease
inhibitors. EB were either not extracted (lane 1) or extracted with 2%
Sarkosyl in the presence of the protease inhibitor
antipain-dihydrochloride (lane 2), bestatin (lane 3), chymostatin (lane
4), E-64 (lane 5), leupeptin (lane 6), pepstatin (lane 7),
phosphoramidon (lane 8), Pefabloc (lane 9), or aprotinin (lane 10) or
in the absence of protease inhibitor (lane 11).
|
|
Evidence for strain variation among different C. pneumoniae strains.
The foregoing experiments were all
conducted with the CWL029 strain of C. pneumoniae used in
the original genome sequence (9). Given the variation of
Pmp expression, it is pertinent to consider whether there is stability
of Pmp expression phenotype among strains of C. pneumoniae.
Thus, each of the Pmp sera were tested using EB lysates of TW183
(7) and several Pmp sera were also tested with AR39
(16). Similar antigens were detected by immunoblot
analysis for each of the strains (data not shown), including the
doublet antigens for PmpG11, with several exceptions. Anti-PmpG1,
anti-PmpG3, and anti-PmpG10, which did not detect antigens for their
respective gene products in CWL029, detected antigens in TW183 (Fig.
7). This was surprising since
pmpG3 and pmpG10 are predicted to contain
frameshifted open reading frames for CWL029. The sequences flanking the
frameshift for pmpG3 and pmpG10 were amplified
from TW183 and sequenced. The frameshift for pmpG10 was
resolved in TW183 from the loss of two guanine bases and was also
resolved in AR39 by the addition of a guanine residue. However, the
sequence for pmpG3 appeared to conserve the frameshift.
Interestingly the immunoreactive band to PmpG6 for CWL029 had a
molecular weight of 100,000, although the protein is predicted to be
144,000 Da. Moreover, a 130,000-molecular-weight antigen was detected
for both TW183 and AR39 (Fig. 8). PmpG6
for AR39 is predicted to have a molecular weight of 131,000 because its
gene contains 393 fewer nucleotides (16) compared to the CWL029 homolog. The pmpG6 gene encodes a 131-amino-acid
sequence that is repeated in CWL029 three times (8) but is
only repeated in AR39 twice (Fig. 9).
Based on sequence homology of the repeats between C. pneumoniae strains, the additional repeat in CWL029 is the second
in the series (amino acids 429 to 559). Its origin is probably from the
first repeat since its sequence is most similar to the first of the
repeats.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 7.
Detection of PmpG1, PmpG3, and PmpG10 in TW183 (lane 2)
but not in CWL029 (lane 1). The sizes of molecular weight markers are
shown on the left in thousands.
|
|

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 8.
Variation in PmpG6 molecular weight among C. pneumoniae strains. Immnoblots of EB lysates obtained from
C. pneumoniae CWL029, TW183, and AR39 probed with anti-PmpG2
and anti-PmpG6 are shown. The sizes of molecular weight markers are
shown on the left in thousands.
|
|
 |
DISCUSSION |
One of the many surprising findings following the completion of
the C. pneumoniae genome sequence was the presence of a
large family of 21 related pmp genes predicted to encode
outer membrane proteins (9). The diversity of these genes
is remarkable since there is little nucleotide or amino acid sequence
identity (<50%), but they are strongly related by the presence of
conserved amino acid GGA(I,L,V) and FXXN repeats in the aminoterminal
half of each protein. The pmp family represents >5% of the
total coding capacity of the genome and 22% of the increased coding
capacity of C. pneumoniae versus C. trachomatis
(8). Thus, considerable commitment has been made to
maintaining and diversifying this family in C. pneumoniae.
Phylogenetic analysis suggests the presence of six related families,
each with at least one C. trachomatis and one C. pneumoniae ortholog (8). The G family in C. pneumoniae contains 13 protein paralogs, but 4 of these are
predicted to encode frameshifts (9). Comparison of
pmp genes based on those determined for CWL029
(9) and AR39 (16) shows that the sequences are nearly identical between these two C. pneumoniae
strains, with only three Pmps containing one or two conserved amino
acid changes (PmpE/F4, PmpG10, and PmpG8), including genes with
predicted frameshifts.
The pmpG10 gene contains a string of 13 guanine residues for
CWL029 that results in a shift out of reading frame; however, AR39
contains 14 guanine residues in this string and is not frameshifted. TW-183 pmpG10 contains 11 guanine residues and is not
frameshifted. Consistent with these sequence predictions, anti-PmpG10
serum reacted with antigens in both AR39 and TW183 but not in CWL029. It also appears significant that the CWL029 strain with a different passage history contains 14 guanine residues and produces a protein product (10). These data suggest that a slip-strand
mechanism altering the number of guanine residues within and between
strains of C. pneumoniae accounts for variation in the
expression of PmpG10. This conclusion is supported by the recent report
describing clonal variation in the expression of PmpG10 for another
strain of C. pneumoniae (A. S. Pedersen, S. Birkelund,
and G. Christiansen, Proc. Fourth Meet. Eur. Soc. Chlamydia Res., p.
44, 2000). The C. trachomatis pmpG gene (CT871) contains 9 guanine residues (the longest string of guanine residues in the
genome), suggesting that phase variation is a common phenotype for
PmpG. However, poly(G) tracts are not a characteristic of other
pmp genes. Another difference between AR39 and CWL029 is
pmpG6, that in CWL029 encodes 131 additional amino acids due
to an apparent tandem duplication of 393 nucleotides. The amplification
of the pmp gene family and the confidently predicted
frameshifts in CWL029 and AR39 suggest a specific molecular mechanism
to promote functional or antigenic diversity.
To begin assessment of the role and mechanisms of Pmp diversity, we
evaluated the expression of each of the pmp genes. RT-PCR analysis revealed that each of the pmp genes in C. pneumoniae, including those with predicted frameshifts, is
transcribed. This is consistent with the previous finding that each of
the nine pmp genes in C. trachomatis is
transcribed (13). Thus, chlamydiae expend a considerable
metabolic cost in pmp transcription despite the potential
lack of production of a functional protein.
We next assessed whether the transcribed pmp genes are
translated. To produce a reagent specific to each Pmp, 20-mer
polypeptide sequences were selected that were unique to each of the 21 predicted coding sequences and the synthetic peptides were used to
produce monospecific antisera that could be used as probes for the
mutually exclusive detection of each Pmp. High-titer antiserum was
elicited to each polypeptide and, with a few exceptions, was found to
be highly specific for the respective polypeptide immunogen and thereby suitable for probing the expression of each Pmp paralog. The
cross-reactivity observed between B/C- and G-family peptides and sera,
although potentially problematic, was mitigated by the finding that the anti-B/C serum did not react to EB proteins. Similar findings for the
other antisera with cross-reactive peptides suggest that those antisera
reactive to proteins in EB lysates were suitable for the detection of
specific Pmp paralogs.
Using each of the Pmp-specific sera to probe immunoblots of EB lysates
enabled the detection of 11 different Pmps. No reactivity was observed
for the remaining 10 Pmp, which included those encoded by the five
frameshifted genes and one truncated gene. Production of antisera to
the amino-terminal open reading frame upstream of the predicted
frameshift also did not reveal a protein product. Based on the
nucleotide sequence and complete coding sequence, it was expected that
PmpA, PmpB/C, and PmpD should be expressed; however, no immunoreactive
bands were detected in CWL029 or TW183. In contrast anti-PmpG1, whose
respective gene also appears to encode a complete protein, was not
reactive to lysates of CWL029 but detected an antigen in TW183. Testing
of TW183 EB lysates revealed immunoreactive bands for PmpG3 and PmpG10,
both with sequence frameshifts in CWL029 and whose proteins were not
detected in lysates of CWL029 EB. These findings demonstrate that there is variation in Pmp expression among strains of C. pneumoniae.
Although the relative insensitivity of immunoblot analysis precludes an
unequivocal conclusion that PmpA, PmpB/C, and PmpD are not expressed,
if present they are minor constituents of the C. pneumoniae
outer membrane. The genes encoding these proteins have nevertheless
been maintained and the reading frames have been preserved in both
CWL029 and AR29. Given our findings of the endogenous protease
sensitivity of at least some of the Pmps, one possibility is that these
three genes are expressed but processed or degraded by proteolytic
digestion, rendering them undetectable by immunoblot analysis. The
presence of two immunoreactive high-molecular-weight antigens for PmpG8
and PmpG11 is consistent with the possibility of proteolytic
modification. The finding of an endogenous protease leads to the
hypothesis that Pmps are subject to posttranslational processing. Of
the eight strongly positive full-length Pmps by immunoblot analysis,
six are members of the PmpG family and the other two are PmpH and
PmpE/F2. It has recently been shown that for C. trachomatis
Pmps, only PmpG and PmpH are highly expressed (15).
Variation in the size of Pmp products was found for PmpG6, whose
molecular weight differed by nearly 13,000 among strains. Comparison of
the pmp gene family for CWL029 and AR39 reveals that only
the pmpG6 gene differs significantly among the 21 orthologs. For the CWL029 strain, the pmpG6 product contains three
tandem repeats of 131 amino acids whereas in AR39 it contains two
repeats. Thus, interstrain variation in Pmp expression may be expected among strains of chlamydiae. Overall, the molecular bases for Pmp
variation is consistent with the notion that slip-strand base pairing
and posttranscriptional mechanisms of regulation play important roles
in Pmp expression.
The function of chlamydial Pmps remains unknown, although based on
sequence prediction (9, 17) and experimental testing (10, 14), these are surface proteins and consequently
likely to be critical to chlamydial virulence. Variation, both within and between strains, is the major theme of the Pmp protein family, evidenced by diversity in sequence, frameshifts, expression, size, and
protease sensitivity. These data suggest that variation is a central
requisite for the function of these proteins in the biology of chlamydiae.
 |
ACKNOWLEDGMENTS |
This work was supported by National Institutes of Health grants
AI40250, AI39258, AI42156, and EY07757. J.G. was supported by a
fellowship from the Francis I. Proctor Foundation for Research in Ophthalmology.
We thank C. Fenner for review and for editing the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Infectious Diseases, School of Public Health, 235 Earl Warren Hall,
University of California, Berkeley, CA 94720-7360. Phone: (510)
643-9900. Fax: (510) 643-1537. E-mail:
rss{at}uclink4.berkeley.edu.
Present address: Stanford Human Genome Center, Palo Alto, CA 94304.
Editor:
D. L. Burns
 |
REFERENCES |
| 1.
|
Belland, R. J.,
S. G. Morrison,
J. H. Carlson, and D. M. Hogan.
1997.
Promoter strength influences phase variation of neisserial opa genes.
Mol. Microbiol.
23:123-135[CrossRef][Medline].
|
| 2.
|
Caldwell, H. D.,
J. Kromhout, and J. Schachter.
1981.
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.
Infect. Immun.
31:1161-1176[Abstract/Free Full Text].
|
| 3.
|
Campbell, L. A.,
C. C. Kuo, and J. T. Grayston.
1998.
Chlamydia pneumoniae and cardiovascular disease.
Emerg. Infect. Dis.
4:571-579[Medline].
|
| 4.
|
Carrington, M., and J. Boothroyd.
1996.
Implications of conserved structural motifs in disparate trypanosome surface proteins.
Mol. Biochem. Parasitol.
81:119-126[CrossRef][Medline].
|
| 5.
|
Grayston, J. T.
1999.
Does Chlamydia pneumoniae cause atherosclerosis?
Arch. Surg.
134:930-934[Free Full Text].
|
| 6.
|
Grayston, J. T.,
M. B. Aldous,
A. Easton,
S. P. Wang,
C. C. Kuo,
L. A. Campbell, and J. Altman.
1993.
Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.
J. Infect. Dis.
168:1231-1235[Medline].
|
| 7.
|
Grayston, J. T.,
C. C. Kuo,
L. A. Campbell, and S. P. Wang.
1989.
Chlamydia pneumoniae sp. nov. for Chlamydia strain TWAR.
Int. J. Syst. Bacteriol.
39:88[Abstract/Free Full Text].
|
| 8.
|
Grimwood, J.,
W. Mitchell, and R. S. Stephens.
1998.
Phylogenetic analysis of a multigene family conserved between Chlamydia trachomatis and Chlmaydia pneumoniae, p. 263-266.
In
R. S. Stephens, G. I. Byrne, G. Christiansen, I. N. Clarke, J. T. Grayston, R. G. Rank, G. L. Ridgway, P. Saikku, J. Schachter, and W. E. Stamm (ed.), Chlamydial infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infection. International Chlamydia Symposium, San Francisco, Calif.
|
| 9.
|
Kalman, S.,
W. Mitchell,
R. Marathe,
C. Lammel,
J. Fan,
R. W. Hyman,
L. Olinger,
J. Grimwood,
R. W. Davis, and R. S. Stephens.
1999.
Comparative genomes of Chlamydia pneumoniae and C. trachomatis.
Nat. Genet.
21:385-389[CrossRef][Medline].
|
| 10.
|
Knudsen, K.,
A. S. Madsen,
P. Mygind,
G. Christiansen, and S. Birkelund.
1999.
Identification of two novel genes encoding 97- to 99-kilodalton outer membrane proteins of Chlamydia pneumoniae.
Infect. Immun.
67:375-383[Abstract/Free Full Text].
|
| 11.
|
Koehler, J. E.,
R. R. Burgess,
N. E. Thompson, and R. S. Stephens.
1990.
Chlamydia trachomatis RNA polymerase major subunit. Sequence and structural comparison of conserved and unique regions with Escherichia coli 70 and Bacillus subtilis 43.
J. Biol. Chem.
265:13206-13214[Abstract/Free Full Text].
|
| 12.
|
Lindholt, J. S.,
H. Fasting,
E. W. Henneberg, and L. Ostergaard.
1999.
A review of Chlamydia pneumoniae and atherosclerosis.
Eur. J. Vasc. Endovasc. Surg.
17:283-289[CrossRef][Medline].
|
| 13.
|
Lindquist, E. A., and R. S. Stephens.
1998.
Transcriptional activity of a sequence variable protein family in Chlamydia trachomatis, p. 259-262.
In
R. S. Stephens, G. I. Byrne, G. Christiansen, I. N. Clarke, J. T. Grayston, R. G. Rank, G. L. Ridgway, P. Saikku, J. Schachter, and W. E. Stamm (ed.), Chlamydial infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infection. International Chlamydia Symposium, San Francisco, Calif.
|
| 14.
|
Longbottom, D.,
J. Findlay,
E. Vretou, and S. M. Dunbar.
1998.
Immunoelectron microscopic localisation of the OMP90 family on the outer membrane surface of Chlamydia psittaci.
FEMS Microbiol Lett.
164:111-117[CrossRef][Medline].
|
| 15.
|
Mygind, P. H.,
G. Christiansen,
P. Roepstorff, and S. Birkelund.
2000.
Membrane proteins PmpG and PmpH are major constituents of Chlamydia trachomatis L2 outer membrane complex.
FEMS Microbiol. Lett.
186:163-169[CrossRef][Medline].
|
| 16.
|
Read, T. D.,
R. C. Brunham,
C. Shen,
S. R. Gill,
J. F. Heidelberg,
O. White,
E. K. Hickey,
J. Peterson,
T. Utterback,
K. Berry,
S. Bass,
K. Linher,
J. Weidman,
H. Khouri,
B. Craven,
C. Bowman,
R. Dodson,
M. Gwinn,
W. Nelson,
R. DeBoy,
J. Kolonay,
G. McClarty,
S. L. Salzberg,
J. Eisen, and C. M. Fraser.
2000.
Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39.
Nucleic Acids Res.
28:1397-1406[Abstract/Free Full Text].
|
| 17.
|
Stephens, R. S.,
S. Kalman,
C. Lammel,
J. Fan,
R. Marathe,
L. Aravind,
W. Mitchell,
L. Olinger,
R. L. Tatusov,
Q. Zhao,
E. V. Koonin, and R. W. Davis.
1998.
Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis.
Science
282:754-759[Abstract/Free Full Text].
|
Infection and Immunity, April 2001, p. 2383-2389, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2383-2389.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Thomson, N. R., Yeats, C., Bell, K., Holden, M. T.G., Bentley, S. D., Livingstone, M., Cerdeno-Tarraga, A. M., Harris, B., Doggett, J., Ormond, D., Mungall, K., Clarke, K., Feltwell, T., Hance, Z., Sanders, M., Quail, M. A., Price, C., Barrell, B. G., Parkhill, J., Longbottom, D.
(2005). The Chlamydophila abortus genome sequence reveals an array of variable proteins that contribute to interspecies variation. Genome Res
15: 629-640
[Abstract]
[Full Text]
-
Henderson, I. R., Navarro-Garcia, F., Desvaux, M., Fernandez, R. C., Ala'Aldeen, D.
(2004). Type V Protein Secretion Pathway: the Autotransporter Story. Microbiol. Mol. Biol. Rev.
68: 692-744
[Abstract]
[Full Text]
-
Eko, F. O., He, Q., Brown, T., McMillan, L., Ifere, G. O., Ananaba, G. A., Lyn, D., Lubitz, W., Kellar, K. L., Black, C. M., Igietseme, J. U.
(2004). A Novel Recombinant Multisubunit Vaccine against Chlamydia. J. Immunol.
173: 3375-3382
[Abstract]
[Full Text]
-
Gomes, J. P., Bruno, W. J., Borrego, M. J., Dean, D.
(2004). Recombination in the Genome of Chlamydia trachomatis Involving the Polymorphic Membrane Protein C Gene Relative to ompA and Evidence for Horizontal Gene Transfer. J. Bacteriol.
186: 4295-4306
[Abstract]
[Full Text]
-
Li, Y.-C., Korol, A. B., Fahima, T., Nevo, E.
(2004). Microsatellites Within Genes: Structure, Function, and Evolution. Mol Biol Evol
21: 991-1007
[Abstract]
[Full Text]
-
Vretou, E., Giannikopoulou, P., Longbottom, D., Psarrou, E.
(2003). Antigenic Organization of the N-Terminal Part of the Polymorphic Outer Membrane Proteins 90, 91A, and 91B of Chlamydophilaabortus. Infect. Immun.
71: 3240-3250
[Abstract]
[Full Text]
-
Rocha, E. P. C., Pradillon, O., Bui, H., Sayada, C., Denamur, E.
(2002). A new family of highly variable proteins in the Chlamydophila pneumoniae genome. Nucleic Acids Res
30: 4351-4360
[Abstract]
[Full Text]
-
Lindquist, E. A., Marks, J. D., Kleba, B. J., Stephens, R. S.
(2002). Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiology
148: 443-451
[Abstract]
[Full Text]
-
Montigiani, S., Falugi, F., Scarselli, M., Finco, O., Petracca, R., Galli, G., Mariani, M., Manetti, R., Agnusdei, M., Cevenini, R., Donati, M., Nogarotto, R., Norais, N., Garaguso, I., Nuti, S., Saletti, G., Rosa, D., Ratti, G., Grandi, G.
(2002). Genomic Approach for Analysis of Surface Proteins in Chlamydia pneumoniae. Infect. Immun.
70: 368-379
[Abstract]
[Full Text]